Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation
1 other identifier
observational
300
1 country
1
Brief Summary
In this study, the continuous inclusion of atrial fibrillation patients treated by catheter ablation in the Department of Cardiology, Peking University Third Hospital, through the collection of clinical data and outpatient follow-up, to explore the risk factors of atrial fibrillation recurrence after catheter ablation and the influencing factors of major clinical events in atrial fibrillation patients, and further guide the management mode of atrial fibrillation patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 28, 2022
CompletedFirst Posted
Study publicly available on registry
December 6, 2022
CompletedStudy Start
First participant enrolled
January 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedFebruary 21, 2024
December 1, 2023
2 years
November 28, 2022
February 19, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Compound cardiovascular event
Stroke, hemorrhage, re-hospitalization for atrial fibrillation and heart failure, and all-cause death
24 months
Study Arms (1)
atrial fibrillation
After radiofrequency ablation of patients with atrial fibrillation
Interventions
This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
Eligibility Criteria
In this study, atrial fibrillation patients who meet the inclusion criteria and those who do not meet the exclusion criteria were admitted to the Department of Cardiology of Peking University Third Hospital after catheter ablation from December 31, 2022 to December 31, 2023
You may qualify if:
- \) Age \> 18
- \) ECG or holter electrocardiogram confirmed atrial fibrillation
You may not qualify if:
- \) Hematological diseases, autoimmune diseases and malignant tumors
- \) Immobility caused by hemiplegia or severe trauma
- \) The expected survival time is less than 2 years
- \) Poor compliance and high risk of expected loss of follow-up
- \) Disorders of consciousness or Alzheimer's disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking-University-Third-Hospital
Beijing, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 28, 2022
First Posted
December 6, 2022
Study Start
January 1, 2023
Primary Completion
December 31, 2024
Study Completion (Estimated)
December 31, 2026
Last Updated
February 21, 2024
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share